Đang chuẩn bị liên kết để tải về tài liệu:
Báo cáo y học: "Therapeutic effect of the potent IL-12/IL-23 inhibitor STA-5326 on experimental autoimmune uveoretinitis"

Tuyển tập các báo cáo nghiên cứu về y học được đăng trên tạp chí y học General Psychiatry cung cấp cho các bạn kiến thức về ngành y đề tài: Therapeutic effect of the potent IL-12/IL-23 inhibitor STA-5326 on experimental autoimmune uveoretinitis. | Available online http arthritis-research.eom content 10 5 R122 Research article Therapeutic effect of the potent IL-12 IL-23 inhibitor STA-5326 on experimental autoimmune uveoretinitis Hiroshi Keino1 Takayo Watanabe1 Yasuhiko Sato2 Mamoru Niikura3 Yumiko Wada4 and Annabelle A Okada1 Department of Ophthalmology Kyorin University School of Medicine 6-20-2 Shinkawa Mitaka Tokyo 181-8611 Japan division of Radioisotope Research Kyorin University School of Medicine 6-20-2 Shinkawa Mitaka Tokyo 181-8611 Japan laboratory of Animals Kyorin University School of Medicine 6-20-2 Shinkawa Mitaka Tokyo 181-8611 Japan 4Synta Pharmaceuticals Corporation 45 Hartwell Ave. Lexington MA 02421 USA Corresponding author Hiroshi Keino keino@eye-center.org Received 8 Aug 2008 Revisions requested 4 Sep 2008 Revisions received 1 7 Sep 2008 Accepted 13 Oct 2008 Published 13 Oct 2008 Arthritis Research Therapy 2008 10 R122 doi 10.11 86 ar2530 This article is online at http arthritis-research.com content 10 5 R122 2008 Keino et al. licensee BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License http creativecommons.org licenses by 2.0 which permits unrestricted use distribution and reproduction in any medium provided the original work is properly cited. Open Access Abstract Introduction The purpose of this study was to determine if oral administration of the interleukin IL 12 IL-23 inhibitor STA-5326 is effective in experimental autoimmune uveoretinitis EAU . Methods C57BL 6J mice were immunised with human interphotoreceptor retinoid binding protein peptide IRBP1-20 . STA-5326 at a dose of either 5 mg kg or 20 mg kg or vehicle alone was orally administered once a day for six days a week from day 0 to day 14. Fundus examination was performed on day 14 and day 18 after immunisation. Mice were euthanased on day 18 and the eyes were enucleated for histopathological examination. In vivo-primed draining lymph node cells were .